OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Combination Approaches for Metastatic Renal Cell Carcinoma

home / insights / mrcc-combination-approaches
Advertisement
Historical Perspectives on the Treatment of mRCC

EP. 1: Historical Perspectives on the Treatment of mRCC

July 30th 2018
Rationale for Combination Therapy in mRCC

EP. 2: Rationale for Combination Therapy in mRCC

July 30th 2018
Cabozantinib in mRCC

EP. 3: Cabozantinib in mRCC

July 30th 2018
Nivolumab and Ipilimumab in mRCC

EP. 4: Nivolumab and Ipilimumab in mRCC

July 30th 2018
Bevacizumab and Interferon in mRCC

EP. 5: Bevacizumab and Interferon in mRCC

July 30th 2018
Antiangiogenic Resistance in mRCC

EP. 6: Antiangiogenic Resistance in mRCC

July 30th 2018
Advertisement
Making Decisions for Second-Line Therapy in mRCC

EP. 7: Making Decisions for Second-Line Therapy in mRCC

July 30th 2018
Second-Line Combination Therapy in mRCC

EP. 8: Second-Line Combination Therapy in mRCC

July 30th 2018
Lenvatinib and Everolimus in Relapsed/Refractory mRCC

EP. 9: Lenvatinib and Everolimus in Relapsed/Refractory mRCC

July 30th 2018
Managing Patients on Lenvatinib/Everolimus in mRCC

EP. 10: Managing Patients on Lenvatinib/Everolimus in mRCC

July 30th 2018
Therapeutic Sequencing in mRCC

EP. 11: Therapeutic Sequencing in mRCC

July 30th 2018
TKI/I-O Therapy in mRCC

EP. 12: TKI/I-O Therapy in mRCC

July 30th 2018
Advertisement
Emerging TKI/I-O Options in mRCC

EP. 13: Emerging TKI/I-O Options in mRCC

July 30th 2018
Novel Combination Therapies Under Investigation in mRCC

EP. 14: Novel Combination Therapies Under Investigation in mRCC

July 30th 2018
PD-L1 Testing in mRCC

EP. 15: PD-L1 Testing in mRCC

July 30th 2018
Future Directions for Research in mRCC

EP. 16: Future Directions for Research in mRCC

July 30th 2018

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact